Apply for grants

DKK 60 Million for Innovative Interdisciplinary Research

The Novo Nordisk Foundation has awarded the first four grants in the new Interdisciplinary Synergy Programme.

Many health challenges and questions require solutions that cannot be found through a single traditional scientific discipline. The Programme therefore aims to provide support for innovative, high-risk interdisciplinary research with a biomedical and/or biotechnological objective.

The Foundation wants the Programme to promote an innovative research culture in Denmark by creating vital scientific synergy that is inherently high risk and high gain. Interdisciplinary research involves research groups spanning different disciplines collaborating closely to answer a common research question. The ambition is that collaboration will generate greater scientific dividends than those individual groups would produce.

Up to DKK 60 million is being awarded annually for up to four projects, which will receive DKK 15 million per year for 3 years.

Based on the recommendations of the Foundation’s Committee on the Interdisciplinary Synergy Programme, the Board of the Foundation has selected four grant recipients in 2014.



HARTWIG R. SIEBNER, Professor, Head of Research, Danish Research Centre for Magnetic Resonance (DRCMR), Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Hvidovre.

Project title: Biophysically adjusted state-informed cortex stimulation (BASICS): shaping the functional architecture of neural networks to improve human brain function.

Co-applicants: Lars Kai Hansen, Professor, Cognitive Systems, Technical University of Denmark Compute; and Axel Thielscher, Associate Professor, Biomedical Engineering, Technical University of Denmark Electrical Engineering.


JACOB TFELT-HANSEN, Clinical Associate Professor, Department of Cardiology, Rigshospitalet – Copenhagen University Hospital.

Project title: Risk factors for sudden cardiac death during acute myocardial infarction (MI-RISK).

Co-applicants: Thomas Jespersen, Associate Professor, Danish Arrhythmia Research Centre, University of Copenhagen; Christine M. Albert, Division of Preventive Medicine, Brigham and Women’s Hospital and Associate Professor, Harvard Medical School, Boston, MA, USA; and Molly Maleckar, Simula Research Laboratory (non-profit), Oslo, Norway.


LENE B. ODDERSHEDE, Associate Professor, Niels Bohr Institute, University of Copenhagen.

Project title: Laser-activated nanoparticles for tumour elimination (LANTERN).

Co-applicants: Andreas Kjær, Professor, Nuclear Medicine and PET, Rigshospitalet – Copenhagen University Hospital; Poul Martin Bendix, Associate Professor, Niels Bohr Institute, University of Copenhagen; and Naomi Halas, Professor, Electrical and Computer Engineering, Rice University, Houston, TX, USA.


SØREN KRAGH MOESTRUP, Professor, Department of Molecular Medicine, University of Southern Denmark.

Project title: Development of “next-generation” antibody–drug conjugates for targeting endocytic receptors in a ligand-mimicking fashion.

Co-applicants: Thomas Andresen, Professor, Technical University of Denmark Nanotech; Toby Lawrence, Inflammation Biology Group, Marseille, France; and Jacob Fog Bentzon, Associate Professor, Department of Clinical Medicine, Aarhus University Hospital.


Christian Mostrup Scheel, Press Officer, Novo Nordisk Foundation, [email protected], mobile: +45 30674805.